Osteopore (ASX:OSX), an Australian and Singapore based company involved in the manufacture of regenerative implants, had announced the appointment of Dr Lim Jing as its chief operating officer.
Dr Jing most recently served as the company's chief technology officer and will also continue in that role.
In his new role, Dr Jing will be responsible for overseeing the company's daily business and administrative operations, assessing and enhancing the efficiency of internal and external operational processes, and collaborating with management and other stakeholders to identify initiatives to increase the value of the company.
Dr Jing’s operational scope will expand to allow for the increased utilisation of the company’s tissue regeneration technology across new applications, and accelerate the development of next-generation implants to access multiple billion-dollar markets.
Osteopore CEO Goh Khoon Seng said, “Over the period that I have worked with Dr Lim, he has demonstrated outstanding technical expertise, strong leadership and a dedication to Osteopore's commercial vision. He has also been instrumental in improving our underlying technology and manufacturing processes. This new role will be critical in executing additional collaborative partnerships, gaining further regulatory clearances, and launching complementary products for additional bone regeneration applications.”